Home > Insider Trading > Filing (0000899243-23-013289)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658551	Amylyx Pharmaceuticals Inc.	AMLX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1235598	M James Frates	C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02141	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-05-16	32,500	$6.88	88,176	No	4	M	Direct
Common Stock	Disposition	2023-05-16	32,000	$26.93	56,176	No	4	S	Direct
Common Stock	Disposition	2023-05-16	500	$27.60	55,676	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-05-16	32,500	$0.00	32,500	$6.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
382,000		2031-01-25	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	19,482	Indirect	By Trust

Footnotes

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.36 to $27.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.59 to $27.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.